Chronic hepatitis B virus (CHB) is currently treated with either interferon-based or nucleot(s)ide-based antiviral therapies. However, treatment with pegylated interferon alpha results in a durable antiviral response in only about 30% patients and is associated with side effects. Most patients receiving nucleot(s)ide analogue treatment do not establish long-term, durable control of infection and have rebounding viremia after cessation of therapy. Thus, novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication. Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B. Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.
Barber D L, Wherry E J, Masopust D, Zhu B, Allison J P, Sharpe A H, Freeman G J, and Ahmed R. 2006. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature, 439: 682–687.
Blum H E, Gerok W, and Vyas G N. 1989. The molecular biology of hepatitis B virus. Trends Genet: TIG, 5: 154–158.
Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S, Scognamiglio P, Boehme R, Panebianco R, Fiaccadori F, and Ferrari C. 1998. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest, 102: 968–975.
Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, and Ferrari C. 2007. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol, 81: 4215–4225.
Boni C, Penna A, Bertoletti A, Lamonaca V, Rapti I, Missale G, Pilli M, Urbani S, Cavalli A, Cerioni S, Panebianco R, Jenkins J, and Ferrari C. 2003. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol, 39: 595–605.
Chisari F V, Isogawa M, and Wieland S F. 2010. Pathogenesis of hepatitis B virus infection. Pathol Biol, 58: 258–266.
Couillin I, Pol S, Mancini M, Driss F, Brechot C, Tiollais P, and Michel M L. 1999. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis, 180: 15–26.
Dahmen A, Herzog-Hauff S, Bocher W O, Galle P R, and Lohr H F. 2002. Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol, 66: 452–460.
Dandri M, and Locarnini S. 2012. New insight in the pathobiology of hepatitis B virus infection. Gut, 61 Suppl 1: i6–17.
Day C L, Kaufmann D E, Kiepiela P, Brown J A, Moodley E S, Reddy S, Mackey E W, Miller J D, Leslie A J, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry E J, Coovadia H M, Goulder P J, Klenerman P, Ahmed R, Freeman G J, and Walker B D. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature, 443: 350–354.
Dikici B, Bosnak M, Ucmak H, Dagli A, Ece A, and Haspolat K. 2003. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection. J Gastroen Hepatol, 18: 218–222.
Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M, Johrden L, Mayer A, Wildner O, and Roggendorf M. 2013. Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J Virol, 87: 7708–7716.
Finnefrock A C, Tang A, Li F, Freed D C, Feng M, Cox K S, Sykes K J, Guare J P, Miller M D, Olsen D B, Hazuda D J, Shiver J W, Casimiro D R, and Fu T M. 2009. PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol, 182: 980–987.
Freeman G J, Wherry E J, Ahmed R, and Sharpe A H. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med, 203: 2223–2227.
Ganem D, and Prince A M. 2004. Hepatitis B virus infection—natural history and clinical consequences. New Engl J Med, 350: 1118–1129.
Ha S J, Mueller S N, Wherry E J, Barber D L, Aubert R D, Sharpe A H, Freeman G J, and Ahmed R. 2008. Enhancing therapeutic vaccination by blocking PD-1-mediated inhibitory signals during chronic infection. J Exp Med, 205: 543–555.
Hervas-Stubbs S, Lasarte J J, Sarobe P, Vivas I, Condreay L, Cullen J M, Prieto J, and Borras-Cuesta F. 2001. T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol, 35: 105–111.
Horiike N, Fazle Akbar S M, Michitaka K, Joukou K, Yamamoto K, Kojima N, Hiasa Y, Abe M, and Onji M. 2005. In vivo immunization by vaccine therapy following virus suppression by lamivudine: a novel approach for treating patients with chronic hepatitis B. J Clin Virol: the official publication of the Pan American Society for Clinical Virology, 32: 156–161.
Jung M C, Spengler U, Schraut W, Hoffmann R, Zachoval R, Eisenburg J, Eichenlaub D, Riethmuller G, Paumgartner G, Ziegler-Heitbrock H W, and et al. 1991. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol, 13: 310–317.
Jung M C, Gruner N, Zachoval R, Schraut W, Gerlach T, Diepolder H, Schirren C A, Page M, Bailey J, Birtles E, Whitehead E, Trojan J, Zeuzem S, and Pape G R. 2002. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine, 20: 3598–3612.
Kosinska A D, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O, Lu M, and Roggendorf M. 2012. DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol, 86: 9297–9310.
Kosinska A D, Zhang E, Johrden L, Liu J, Seiz P L, Zhang X, Ma Z, Kemper T, Fiedler M, Glebe D, Wildner O, Dittmer U, Lu M, and Roggendorf M. 2013. Combination of DNA prime-adenovirus boost immunization with entecavir elicits sustained control of chronic hepatitis B in the woodchuck model. PLoS Pathog, 9: e1003391.
Li F J, Zhang Y, Jin G X, Yao L, and Wu D Q. 2013. Expression of LAG-3 is coincident with the impaired effector function of HBV-specific CD8(+) T cell in HCC patients. Immunol Lett, 150: 116–122.
Liang T J. 2009. Hepatitis B: the virus and disease. Hepatology, 49: S13–21.
Locarnini S, and Mason W S. 2006. Cellular and virological mechanisms of HBV drug resistance. J Hepatol, 44: 422–431.
Lu M, Yao X, Xu Y, Lorenz H, Dahmen U, Chi H, Dirsch O, Kemper T, He L, Glebe D, Gerlich W H, Wen Y, and Roggendorf M. 2008. Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model. J Virol, 82: 2598–2603.
Maier H, Isogawa M, Freeman G J, and Chisari F V. 2007. PD-1:PD-L1 interactions contribute to the functional suppression of virus-specific CD8+ T lymphocytes in the liver. J Immunol, 178: 2714–2720.
Maini M K, Boni C, Lee C K, Larrubia J R, Reignat S, Ogg G S, King A S, Herberg J, Gilson R, Alisa A, Williams R, Vergani D, Naoumov N V, Ferrari C, and Bertoletti A. 2000. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med, 191: 1269–1280.
Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, and Michel M L. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 24: 4482–4489.
Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, and Michel M L. 2004. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology, 40: 874–882.
Menne S, Roneker C A, Tennant B C, Korba B E, Gerin J L, and Cote P J. 2002. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology, 45: 237–250.
Menne S, Roneker C A, Korba B E, Gerin J L, Tennant B C, and Cote P J. 2002. Immunization with surface antigen vaccine alone and after treatment with 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)-uracil (L-FMAU) breaks humoral and cell-mediated immune tolerance in chronic woodchuck hepatitis virus infection. J Virol, 76: 5305–5314.
Paoletti E. 1996. Applications of pox virus vectors to vaccination: an update. P Natl Acad Sci USA, 93: 11349–11353.
Penna A, Chisari F V, Bertoletti A, Missale G, Fowler P, Giuberti T, Fiaccadori F, and Ferrari C. 1991. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med, 174: 1565–1570.
Penna A, Pilli M, Zerbini A, Orlandini A, Mezzadri S, Sacchelli L, Missale G, and Ferrari C. 2007. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology, 45: 588–601.
Perkus M E, Piccini A, Lipinskas B R, and Paoletti E. 1985. Recombinant vaccinia virus: immunization against multiple pathogens. Science, 229: 981–984.
Petrovas C, Casazza J P, Brenchley J M, Price D A, Gostick E, Adams W C, Precopio M L, Schacker T, Roederer M, Douek D C, and Koup R A. 2006. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med, 203: 2281–2292.
Pilli M, Zerbini A, Penna A, Orlandini A, Lukasiewicz E, Pawlotsky J M, Zeuzem S, Schalm S W, von Wagner M, Germanidis G, Lurie Y, Esteban J I, Haagmans B L, Hezode C, Lagging M, Negro F, Homburger Y, Neumann A U, Ferrari C, and Missale G. 2007. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project). Gastroenterology, 133: 1132–1143.
Pol S, Driss F, Michel M L, Nalpas B, Berthelot P, and Brechot C. 1994. Specific vaccine therapy in chronic hepatitis B infection. Lancet, 344: 342.
Pol S, Nalpas B, Driss F, Michel M L, Tiollais P, Denis J, and Brecho C. 2001. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol, 34: 917–921.
Rehermann B, and Nascimbeni M. 2005. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol, 5: 215–229.
Ren F, Hino K, Yamaguchi Y, Funatsuki K, Hayashi A, Ishiko H, Furutani M, Yamasaki T, Korenaga K, Yamashita S, Konishi T, and Okita K. 2003. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection. J Med Virol, 71: 376–384.
Robinson H L. 2002. New hope for an AIDS vaccine. Nature reviews. Immunology, 2: 239–250.
Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A, Rowe M, Alper R, Klein A, Hemed N, Segol O, Thalenfeld B, Engelhardt D, Rabbani E, and Ilan Y. 2003. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol, 98: 2505–2515.
Sallberg M, Hughes J, Javadian A, Ronlov G, Hultgren C, Townsend K, Anderson C G, O’Dea J, Alfonso J, Eason R, Murthy K K, Jolly D J, Chang S M, Mento S J, Milich D, and Lee W T. 1998. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gene Ther, 9: 1719–1729.
Schurich A, Khanna P, Lopes A R, Han K J, Peppa D, Micco L, Nebbia G, Kennedy P T, Geretti A M, Dusheiko G, and Maini M K. 2011. Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection. Hepatology, 53: 1494–1503.
Tatsis N, and Ertl H C. 2004. Adenoviruses as vaccine vectors. Mol Ther, 10: 616–629.
Thimme R, Wieland S, Steiger C, Ghrayeb J, Reimann K A, Purcell R H, and Chisari F V. 2003. CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol, 77: 68–76.
Trautmann L, Janbazian L, Chomont N, Said E A, Gimmig S, Bessette B, Boulassel M R, Delwart E, Sepulveda H, Balderas R S, Routy J P, Haddad E K, and Sekaly R P. 2006. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med, 12: 1198–1202.
Vandepapeliere P, Lau G K, Leroux-Roels G, Horsmans Y, Gane E, Tawandee T, Merican M I, Win K M, Trepo C, Cooksley G, Wettendorff M, and Ferrari C. 2007. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine, 25: 8585–8597.
Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford T H, Chennareddi L, Silvestri G, Freeman G J, Ahmed R, and Amara R R. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature, 458: 206–210.
Wang X Y, Zhang X X, Yao X, Jiang J H, Xie Y H, Yuan Z H, and Wen Y M. 2010. Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine, 28: 8169–8174.
Webster G J, Reignat S, Brown D, Ogg G S, Jones L, Seneviratne S L, Williams R, Dusheiko G, and Bertoletti A. 2004. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol, 78: 5707–5719.
Wen Y M, Wu X H, Hu D C, Zhang Q P, and Guo S Q. 1995. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet, 345: 1575–1576.
Wu C, Shi H, Wang Y, Lu M, Xu Y, and Chen X. 2012. A case of hepatitis B reactivation due to the hepatitis B virus escape mutant in a patient undergoing chemotherapy. Virol Sin, 27: 369–372.
Wu W, Shi Y, Li S, Zhang Y, Liu Y, Wu Y, and Chen Z. 2012. Blockade of Tim-3 signaling restores the virus-specific CD8(+) T-cell response in patients with chronic hepatitis B. Eur J Immunol, 42: 1180–1191.
Xu D Z, Zhao K, Guo L M, Li L J, Xie Q, Ren H, Zhang J M, Xu M, Wang H F, Huang W X, Bai X F, Niu J Q, Liu P, Chen X Y, Shen X L, Yuan Z H, Wang X Y, and Wen Y M. 2008. A randomized controlled phase IIb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PloS One, 3: e2565.
Xu D Z, Wang X Y, Shen X L, Gong G Z, Ren H, Guo L M, Sun A M, Xu M, Li L J, Guo X H, Zhen Z, Wang H F, Gong H Y, Xu C, Jiang N, Pan C, Gong Z J, Zhang J M, Shang J, Xu J, Xie Q, Wu T F, Huang W X, Li Y G, Yuan Z H, Wang B, Zhao K, and Wen Y M. 2013. Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol, 59: 450–456.
Yalcin K, Acar M, and Degertekin H. 2003. Specific hepatitis B vaccine therapy in inactive HBsAg carriers: a randomized controlled trial. Infection, 31: 221–225.
Yang P L, Althage A, Chung J, Maier H, Wieland S, Isogawa M, and Chisari F V. 2010. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A, 107: 798–802.
Yao X, Zheng B, Zhou J, Xu D Z, Zhao K, Sun S H, Yuan Z H, and Wen Y M. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25: 1771–1779.
Zoulim F, and Locarnini S. 2009. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology, 137: 1593–1608 e1591–1592.
Rights and permissions
About this article
Cite this article
Liu, J., Kosinska, A., Lu, M. et al. New therapeutic vaccination strategies for the treatment of chronic hepatitis B. Virol. Sin. 29, 10–16 (2014). https://doi.org/10.1007/s12250-014-3410-5
- hepatitis B virus
- woodchuck hepatitis virus
- therapeutic vaccination
- programmed death-1